Next, our data indicated that miR-6734-3p and ZEB2 were also influenced by cisplatin treatment, and the results showed that continuous low-dose cisplatin pressure suppressed miR-6734-3p (P < 0.05, Figure 5(d)), while elevated ZEB2 in CR-NSCLC cells (P < 0.05, Figure 5(e)). Here, ZEB2 is linked to non-small cell lung carcinoma.